Effects of combination of omalizumab and olofatadine on the improvement of symptoms of refractory chronic spontaneous urticaria and and its influence on serum immunoglobulin E and T cell subsets
10.3760/cma.j.cn115455-20250304-00206
- VernacularTitle:奥马珠单抗与奥洛他定联用对难治性慢性特发性荨麻疹的症状改善及对血清免疫球蛋白E、T细胞亚群的影响
- Author:
Runze WU
1
Author Information
1. 浙江中医药大学，杭州 310053
- Publication Type:Journal Article
- Keywords:
Urticaria;
Omalizumab;
Olofatadine;
Immunoglobulin E;
Receptors, antigen, T-cell
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(12):1107-1112
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of combination of omalizumab and olofatadine on the improvement of symptoms of refractory chronic spontaneous urticaria (CSU) and its influence on serum immunoglobulin E (IgE) and T cell subsets.Methods:A prospective study was conducted to include 100 patients with refractory CSU who were treated at the Hangzhou Linping District Hospital of Integrated Traditional Chinese and Western Medicine from January 2022 to December 2023. They were divided into the control group and the study group by random number table method. The control group was given olopatadine, 5 mg/ time, 2 times/d, orally; the study group was given the same dose of olofatadine as the control group, plus omazumab, 300 mg/4 weeks, subcutaneous injection. The clinical efficacy of the two groups was compared. The levels of IgE, interleukin-4 (IL-4), interferon -γ (IFN-γ) and T cell subsets before treatment and 12 weeks after treatment were compared between the two groups. The symptom scores and the occurrence of adverse reactions before and after treatment were compared between the two groups.Results:The effective rate in the study group was higher than that in the control group : 96.00% (48/50) vs. 82.00% (41/50), there was statistical difference ( χ2 = 5.01, P<0.05). After treatment, the levels of IgE and IL-4 in the study group were lower than those in the control group : (74.26 ± 12.34) kU/L vs. (93.12 ± 14.62) kU/L, (25.13 ± 3.47) ng/L vs. (29.35 ± 5.24) ng/L, while the level of IFN-γ was higher than that in the control group : (12.72 ± 1.86) ng/L vs. (11.15 ± 1.59) ng/L, there were statistical differences ( P<0.01). After treatment, the level of CD 4+/CD 8+ in the study group was higher than that in the control group 1.50 ± 0.13 vs. 1.01 ± 0.24, there was statistical difference ( P<0.01). After treatment, the scores of refractory CUS symptoms, such as the number of wheals, wheal diameter, pruritus degree and duration in the study group were lower than those in the control group, there were statistical differences ( P<0.05). The total proportion of patients with adverse reactions in the two groups had no statistical difference ( P>0.05). Conclusions:In the treatment of refractory CSU, the combination of omazumab and olatadine can reduce IgE level, improve serum factor indexes, promote the restoration of T cell subpopulation balance, and improve wind mass, pruritosis and other symptoms, with significant clinical efficacy and certain drug safety.
